EGFR and non-small cell lung carcinoma: Multiple studies have demonstrated that EGFR mutations in NSCLC are more likely to correlate with an immunosuppressive TME [41, 43–48], the tumor mutation burden (TMB) [43, 49], and expression of PD-L1 [41, 50–53].